scholarly journals Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II

2017 ◽  
Vol 69 (7) ◽  
pp. 1451-1460 ◽  
Author(s):  
Elizabeth R. Volkmann ◽  
Donald P. Tashkin ◽  
Ning Li ◽  
Michael D. Roth ◽  
Dinesh Khanna ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease

Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease

2010 ◽  
Vol 29 (10) ◽  
pp. 1167-1168 ◽  
Author(s):  
Athanasios Koutroumpas ◽  
Athanasios Ziogas ◽  
Ioannis Alexiou ◽  
Georgia Barouta ◽  
Lazaros I. Sakkas
Keyword(s):  
Mycophenolate Mofetil ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease

Use of Mycophenolate Mofetil for Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease: Information from a Japanese Hospital Claims Database

2021 ◽  
Author(s):  
Takashi Funatogawa ◽  
Yusuke Narita ◽  
Aya Tamura ◽  
Kazuma Mii ◽  
Yasuo Sugitani ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Patient Characteristics ◽  
Limited Information ◽  
Off Label Use ◽  
Claims Database ◽  
Off Label ◽  
Disease Information

Abstract Objectives Limited information is available on patients with systemic sclerosis (SSc) or SSc-associated interstitial lung disease (SSc-ILD) receiving mycophenolate mofetil (MMF) in Japan. The dose, treatment duration, and patient characteristics of SSc and SSc-ILD patients receiving MMF were investigated. Method We used data from a Japanese hospital claims database (2008–2020). Results Data on 486 SSc patients ≥18 years old receiving MMF were captured; 314 had SSc complicated with ILD. The most common initial daily doses were 1000 mg (SSc, 39.5%; SSc-ILD, 38.1%) and 500 mg (SSc, 36.6%; SSc-ILD, 34.6%). The most common maximum daily doses were 1000 mg (SSc, 33.3%; SSc-ILD, 34.9%), 1500 mg (SSc, 24.4%; SSc-ILD, 23.1%), and 2000 mg (SSc, 23.8%; SSc-ILD, 24.4%). Doses ranged from 250 to 3000 mg/day and were similar for SSc and SSc-ILD patients. Over 27% of patients received treatment for >1 year. There was a gradual decrease in steroid doses during MMF treatment. Conclusions Our study suggests that the off-label use of MMF for SSc and SSc-ILD has been increasing annually since 2015 in Japan. The doses used in patients with SSc and SSc-ILD were similar to the approved doses of MMF for lupus nephritis in Japan.

Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease

2016 ◽  
Vol 1 (2) ◽  
pp. 234-240 ◽  
Author(s):  
David Launay ◽  
Anne-Laure Buchdahl ◽  
Alice Berezné ◽  
Pierre-Yves Hatron ◽  
Eric Hachulla ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease

scholarly journals Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Argyris Tzouvelekis ◽  
Nikolaos Galanopoulos ◽  
Evangelos Bouros ◽  
George Kolios ◽  
George Zacharis ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Mean Difference ◽  
Weighted Mean ◽  
Safety And Efficacy ◽  
Efficacy Profile

Background. Interstitial lung disease (ILD) is the most common complication of systemic sclerosis (SSc) with treatment ineffective. Objective: The aim of this meta-analysis was to provide an estimate of the safety and efficacy profile of Mycophenolate Mofetil (MMF) or sodium (MMS) in SSc-ILD patients.Materials and Methods. All studies were reviewed systematically. The main end-points were safety and efficacy profile as estimated by forced vital capacity (FVC)% and diffusion capacity of the lung for carbon monoxide (DLCO)% of the predicted normal value (%pred.) before and after treatment in patients with SSc-ILD. Quality assessment and data extraction were performed independently by two reviewers.Results. Seventeen studies were reviewed systematically. Six studies, one prospective, were eligible for analysis encompassing 69 patients, including 10 subjects from our, yet unpublished, retrospective study. There was no statistically significant difference in both efficacy outcomes of interest, including FVC% pred. (weighted mean difference 1.48, 95% confidence interval (CI): −2.77 to 5.72,P=0.49) and DLCO% pred. (weighted mean difference −0.83, 95% CI: −4.75 to 3.09,P=0.93). No cases of clinically significant side effects were documented.Conclusions. Meta-analysis data suggest that MMF is a safe therapeutic modality which was associated with functional stabilization in patients with SSc-ILD.

Mycophenolate in scleroderma-associated interstitial lung disease: Real-world data from rheumatology and pulmonology clinics in South Asia

2021 ◽  
pp. 239719832110244
Author(s):  
Ramya Janardana ◽  
Aparna Irodi ◽  
Pramod P Chebbi ◽  
Ruchika Goel ◽  
Leena R Vimala ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Mycophenolate Mofetil ◽  
Systemic Sclerosis ◽  
High Resolution ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Forced Vital Capacity ◽  
Vital Capacity ◽  
High Resolution Computed Tomography

Introduction: There is a paucity of real-world data on mycophenolate mofetil/mycophenolate sodium in systemic sclerosis-related interstitial lung disease. Aim: To study the efficacy of mycophenolate mofetil/ mycophenolate sodium in systemic sclerosis-related interstitial lung disease. Methods: In this single-centre study, clinical, laboratory and imaging details of consecutive patients with systemic sclerosis-related interstitial lung disease receiving mycophenolate mofetil/mycophenolate sodium from rheumatology and pulmonology clinics between January 2008 and March 2017 were retrospectively retrieved. The change in percentage of predicted normal forced vital capacity at last follow-up visit as compared with baseline was studied. In addition, high-resolution computed tomography scans at baseline and 2-year follow-up visit were scored as either stable/improved or worsened by experienced thoracic radiologists blinded to the clinical details of patients. Results: Altogether, 88 patients (85.2% females) with mean age (SD) of 33.8 years (± 11.3) and median (interquartile range) duration of disease since non-Raynaud’s symptoms of 36 months (13.5–60) were studied. Diffuse systemic sclerosis comprised 85.2% of them. The mean baseline forced vital capacity was 61.2 ± 17.9% and median scores for ground glass opacities and fibrosis in high-resolution computed tomography were 0.5 (0–1.3) and 1 (0–1.3), respectively. At a median follow-up duration of 30 months (interquartile range = 16.5–49), the percentage of forced vital capacity improved by 1.8% (–3.82 to 9.07) as compared with baseline visit ( p = 0.02). In the 2-year follow-up, the ground glass opacity and fibrosis scores in high-resolution computed tomography improved in 17.3% and 7.7% of patients and stabilized in 63.5% and 78.8% patients, respectively. Conclusion: Mycophenolate mofetil/mycophenolate sodium was efficacious in improving /stabilizing forced vital capacity irrespective of the baseline high-resolution computed tomography lung scores in our patients with systemic sclerosis-related interstitial lung disease during the ⩾ 2-year follow-up period.

Sign in / Sign up

Export Citation Format

Share Document